GENE ONLINE|News &
Fennec Submits Hearing Loss Drug for Third Time After Prior FDA Approval Rejections
Fennec’s PEDMARK is designed to prevent ototoxicity in patients aged one month to 18 years old using a novel formulation of sodium thiosulfate. Through clinical trials, Fennec says that PEDMARK is most effectively administered in an intravenous bolus dose within six hours of chemotherapy treatment.
Despite receiving numerous regulatory milestones and praise after successful clinical trials, Fennec struggles to receive FDA approval for its seemingly promising drug.
Despite receiving numerous regulatory milestones and praise after successful clinical trials, Fennec struggles to receive FDA approval for its seemingly promising drug.
It's free! Log in now to read
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
